Published guidance, NICE advice and quality standards

Showing 41 to 50 of 757

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)	TA938	7 December 2023	7 December 2023
Secukinumab for treating moderate to severe hidradenitis suppurativa	TA935	6 December 2023	6 December 2023
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)	TA936	30 November 2023	30 November 2023
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)	TA933	29 November 2023	29 November 2023
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms	TA934	29 November 2023	29 November 2023
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)	TA932	23 November 2023	23 November 2023
Zanubrutinib for treating chronic lymphocytic leukaemia	TA931	22 November 2023	22 November 2023
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments	TA930	15 November 2023	15 November 2023
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction	TA929	1 November 2023	1 November 2023
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine	TA928	1 November 2023	1 November 2023